The "Heavyweight in Three Major Markets" Whale Closed Out Oil Short Position with Profit-Taking, Keeping $48 Million in BTC and Nasdaq Holdings
BlockBeats News, March 16th, according to Hyperinsight monitoring, in the past 4 hours, the address (0x8af7...) marked as "Heavy Positioning in Three Major Markets" has concentrated on taking profit on its CL (WTI Crude Oil) short position, reducing a total of 51,025 contracts, worth about 5.05 million US dollars, with a recorded profit of about 473,000 US dollars.
After this reduction, its CL short position has been reduced to 250,000 US dollars, with an average price of 106.28 US dollars, nearly fully cleared. Currently, the position of this address in the commodity sector has been basically closed out, with the main holdings remaining in the crypto and U.S. stock markets, holding a total of about 48 million US dollars in BTC and NDX100 (XYZ100) long and short positions.
Prior to this, this address, with its altcoin short position, had a total profit of over 50 million US dollars throughout the cycle, and in the past month, it has simultaneously entered the commodity, crypto, and U.S. stock trading markets with a scale exceeding 50 million US dollars, often hedging profits in different directions in the three major mainstream markets.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley senior bond investor turns bullish on US Treasuries for the first time in ten years
US Stock Movement | SuperX AI Technology (SUPX.US) once fell more than 2.5%, hitting an intraday low of $6.46
SuperX AI Technology's stock price declined, falling more than 2.5% at one point.
BUZZ-Pacira BioSciences participated in a Viatris acquisition deal worth 1.65 billions dollars
Latest Update October 8 – Pacira BioSciences (PCRX.O) shares surged by 44%, hitting a more than three-year high at $36.30. If the rally holds, PCRX is poised for its largest single-day gain on record. Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences in a $1.65 billion cash deal, offering $36.50 per share. The offer represents a premium of approximately 44.8% over Pacira’s recent closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris' product portfolio. Viatris shares fell 2.6% to $17.04. JPMorgan stated: “We believe this acquisition will not significantly alter VTRS' overall financial profile in the short or long term, and expect Exparel’s sales to gradually decline post-2030 due to generic market entry.” Both parties expect to complete the transaction by the end of 2026. Including intraday fluctuations, PCRX shares have risen 40.2% year-to-date, while VTRS has gained 36.8%. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters assumes no liability for any damage or losses resulting from the use of automated translation.)
Crypto prices
More
